PubMed Health⌕ Search

Biomedical subjects

J Ou

Publications and source records attributed to J Ou.

44 records · Page 3Linked to original sources
PubMed1995

Cell-specific expression of activin and its two binding proteins in the rat decidua: role of alpha 2-macroglobulin and follistatin.

Rat decidual tissue is formed by two distinct decidual cell populations located either antimesometrially or mesometrially in the uterus. They differ in morphology, the genes they express, the proteins they secrete, and the role they play during pregnancy. Recently, we have shown that rat decidua expresses follistatin and alpha 2-macroglobulin (alpha 2-MG), two binding proteins to activin. In the present study, we determined whether the decidua of pregnant and pseudopregnant rats also expresses activin, whether activin messenger RNA (mRNA) is confined to a particular cell population, and whether it is regulated by its binding proteins. Decidual and placental tissues were collected at different stages of pseudopregnancy or pregnancy. mRNA expression was examined by in situ hybridization, reverse transcription-polymerase chain reaction, and Northern analysis. Developmental studies revealed that activin A became highly expressed in the antimesometrial decidua only from day 11 at a time when this tissue was undergoing extensive degeneration. Very little activin A mRNA could be detected in the mesometrial decidua. However, late in pregnancy, significant expression of activin A mRNA was detected in the mesometrial decidua undergoing extensive cell death at this stage. Developmental study revealed that activin A mRNA became expressed in the antimesometrial decidua only when follistatin mRNA disappeared from this tissue. Furthermore, mesometrial decidua expressing the most alpha 2-MG mRNA had reduced levels of activin A mRNA. These data suggest that follistatin and alpha 2-MG may, by binding to activin, prevent activin A from stimulating the expression of its own gene. To examine this possibility we first established that the rat decidua expresses activin receptor II at a constant level between days 11-15. Then we examined whether follistatin and alpha 2-MG down-regulate activin expression in a simian virus 40-transformed decidual cell line (GG-AD). These cells express activin A mRNA in abundance, very little follistatin, and no alpha 2-MG. Follistatin and alpha 2-MG caused a dose-related decrease in activin A mRNA levels in these cells. The same inhibitory effect was observed with activin A-blocking antibody. In summary, the results of this investigation demonstrate that rat decidual tissue expresses mRNAs for activin A and its two binding proteins; follistatin and alpha 2-MG. The expression of each mRNA is cell specific and developmentally regulated. The finding that both activin-binding proteins and antibody inhibit the expression of activin A in cultured decidual cells suggests that activin regulates its own gene expression in the decidua.(ABSTRACT TRUNCATED AT 400 WORDS)

Activins↗
PubMed1994

Effect of treatment on titer, function, and antigen recognition of serum antibodies to Actinobacillus actinomycetemcomitans in patients with rapidly progressive periodontitis.

Although periodontal treatment by scaling and root planing (SCRP) is known to induce bacteremia, the effect of this procedure on the host immune response is not known. We have determined pre- and post-SCRP immunoglobulin G antibody titers to antigens of Actinobacillus actinomycetemcomitans in the sera of 22 patients with rapidly progressive periodontitis. We also assessed the ability of these sera to enhance phagocytosis and killing of A. actinomycetemcomitans by human polymorphonuclear leukocytes by using a polymorphonuclear leukocyte chemiluminescence (CL) assay. Specific anti-A. actinomycetemcomitans antibody titers were significantly increased at 6 and 12 months after beginning treatment, and CL values were significantly increased at 12 months, whereas mean interproximal pocket depths were significantly decreased at 12 months after beginning treatment. When patients were classified as either seropositive (twice the median titer of control subjects; n = 10) or seronegative (n = 12), both median titers and CL values were significantly increased for the seronegative group at 6 and 12 months after treatment. In the seropositive group, only the median titer was significantly increased at 12 months. Western blot (immunoblot) patterns for six seronegative and six seropositive patients differed remarkably at the baseline. Before treatment, all of the seropositive patients recognized high-molecular-mass lipopolysaccharide (LPS) and a large number of protein components. Patterns were virtually unaffected by therapy. Before treatment, only one of the seronegative patients recognized the LPS smear and none reacted strongly with protein components. Following treatment, slight LPS staining was observed for five of six seronegative patients and detection of protein bands was enhanced in all cases. We conclude that treatment by SCRP induces a humoral immune response, especially in seronegative patients, and that response may play a role in the observed beneficial effects of periodontal treatment.

Adult↗
PubMed1994

[Confirmative test of human semen stain and mixed stain by immunohistochemical method using anti-human sperm monoclonal antibodies].

The stain of the human semen, the mixture of the human semen and vaginal secretion as well as the semen of the bull, goat, pig, dog, rabbit, rat and mouse was examined by the immunohistochemical method using anti-human sperm monoclonal antibodies (SMAB). The result revealed that the SMAB E10 could make a distinction between the human semen, the mixture of the human semen and vaginal secretion, and the seven kinds of animal semen. It is concluded that this method can be used for the species identification of the semen and the mixed stain under the general condition.

Animals↗
PubMed1989

Novel virulence properties of the Salmonella typhimurium virulence-associated plasmid: immune suppression and stimulation of splenomegaly.

Mice infected subcutaneously with wild-type Salmonella typhimurium, SR11, developed a significant splenomegaly when compared with mice infected with an equal number of a plasmid-cured strain. Further, the bacterial load in the spleen at 14 days after infection, measured as colony-forming units per gram tissue, was significantly higher in mice infected with the parent strain than in mice infected with the plasmid-cured strain. These data confirm the previously reported plasmid-associated ability of Salmonella to multiply within the spleen. In addition, lymph node cells (LNC) from mice infected with the parent strain had a significantly reduced ability to proliferate in response to concanavalin A, a T-cell mitogen, and to heat-killed S. typhimurium cells when compared with LNC isolated from mice infected with the plasmid-cured strain. Finally, reintroduction of a functional Tn5-tagged 90-kb plasmid into a plasmid-free strain restored its capacity to cause a marked splenomegaly and to suppress lymph node cell proliferation in BALB/c mice. These data demonstrate that the 90-kb plasmid of highly virulent S. typhimurium strains mediates several novel pathogenic properties in infected mice: (1) enhancement of the ability of Salmonella to multiply within the spleen; (2) stimulation of a splenic inflammatory response as displayed by marked splenomegaly; and (3) a general suppression of lymphocyte responsiveness to both T-cell mitogens and specific Salmonella antigens.

Animals↗
PubMed1988

Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria.

Immunization with radiation-attenuated malaria sporozoites induces potent cellular immune responses, but the target antigens are unknown and have not previously been elicited by subunit vaccines prepared from the circumsporozoite (CS) protein. A method is described here for inducing protective cell-mediated immunity to sporozoites by immunization with attenuated Salmonella typhimurium transformed with the Plasmodium berghei CS gene. These transformants constitutively express CS antigens and, when used to immunize mice orally, colonize the liver, induce antigen-specific cell-mediated immunity, and protect mice against sporozoite challenge in the absence of antisporozoite antibodies. These data indicate that the CS protein contains T cell epitopes capable of inducing protective cell-mediated immunity, and emphasize the importance of proper antigen presentation in generating this response. Analogous, orally administered vaccines against human malaria might be feasible.

Animals↗
PubMed1985

Hybrid hepatitis B virus-host transcripts in a human hepatoma cell.

The human PLC/PRF/5 hepatoma cell line (the Alexander cell) contains at least seven copies of hepatitis B virus (HBV) DNA integrated in its genome; but it selectively expresses the HBV surface antigen (HBsAg) gene and perhaps low levels of the core gene. We have prepared a cDNA library from PLC/PRF/5 cell poly(A)+ RNA and isolated clones containing HBV sequences. Hybridization experiments show that the great majority of HBV-specific RNAs in this cell line contain HBsAg coding sequences and are presumably derived from the HBsAg gene. Primer extension experiments show that these HBsAg mRNAs are, however, derived from multiple initiation sites in the HBsAg gene and involve two promoters: one at the 5' end of the gene that can produce a protein of 45 kDa, and one located in the pre-S region that can produce two proteins of 31 kDa and the mature HBsAg, 25 kDa, respectively. The HBV RNAs are hybrid RNA species that contain HBV sequences at their 5' ends and host DNA sequences at the 3' ends. The great majority of these hybrid RNAs are transcribed from two closely related yet distinct HBV integrants. The viral-host sequences of these two related hybrid RNAs suggest that the related HBV sequences were generated from a parental fragment via duplication, translocation, and mutagenesis. These processes may play a role in HBV-related oncogenesis.

Carcinoma, Hepatocellular↗